Samar Alanazi

HER3 signaling and targeted therapy in cancer

Rosalin Mishra, Hima Patel, Samar Alanazi et al. · Oncology Reviews · 2018 · 183 citations · Full text

Medicine, Cancer Biology, Molecular Medicine +17

Activating HER3 mutations in breast cancer

Rosalin Mishra, Samar Alanazi, Long Yuan et al. · Oncotarget · 2018 · 37 citations · Full text

Medicine, Molecular Biology, Oncology +6

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

Hima Patel, Rosalin Mishra, Nour Yacoub et al. · Cancers · 2021 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels

Long Yuan, Rosalin Mishra, Hima Patel et al. · Cancers · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

Rosalin Mishra, Long Yuan, Hima Patel et al. · International Journal of Molecular Sciences · 2021 · 20 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16